The present work addresses outstanding questions within the field of primary mitochondrial disease biology and treatment, by incorporating methods from structural biology, molecular biology, and animal studies. First, we utilize a mouse model of mitochondrial deoxyribose nucleic acid (mtDNA) disease to demonstrate the potential therapeutic benefit of low-dose chronic rapamycin treatment. Interestingly, rapamycin therapy significantly extends survival, but does so in the absence of correcting the underlying mitochondrial defect. Next, we focus on human cellular models of mtDNA-based diseases, and show that rapamycin treatment does not induce mitochondrial quality control-mediated clearance of pathogenic mtDNA mutation-harboring organelles. Finally, we investigate a mitochondrial disease phenotype at the level of the organelle, by utilizing in situ cryo-electron tomography to demonstrate the ultrastructural consequences of a pathogenic mutation affecting mitochondrial energy production. We conclude by highlighting the insights into disease biology and treatment that can be gained through a multi-level approach integrating techniques from multiple biomedical fields.
| Identifer | oai:union.ndltd.org:columbia.edu/oai:academiccommons.columbia.edu:10.7916/D8J4050F |
| Date | January 2018 |
| Creators | Siegmund, Stephanie |
| Source Sets | Columbia University |
| Language | English |
| Detected Language | English |
| Type | Theses |
Page generated in 0.0019 seconds